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Abstract
Hypothalamic neurons expressing neuropeptide orexins are critically involved in the control of sleep and wakefulness.
Although the activity of orexin neurons is thought to be influenced by various neuronal input as well as humoral factors, the
direct consequences of changes in the activity of these neurons in an intact animal are largely unknown. We therefore
examined the effects of orexin neuron-specific pharmacogenetic modulation in vivo by a new method called the Designer
Receptors Exclusively Activated by Designer Drugs approach (DREADD). Using this system, we successfully activated and
suppressed orexin neurons as measured by Fos staining. EEG and EMG recordings suggested that excitation of orexin
neurons significantly increased the amount of time spent in wakefulness and decreased both non-rapid eye movement
(NREM) and rapid eye movement (REM) sleep times. Inhibition of orexin neurons decreased wakefulness time and increased
NREM sleep time. These findings clearly show that changes in the activity of orexin neurons can alter the behavioral state of
animals and also validate this novel approach for manipulating neuronal activity in awake, freely-moving animals.
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Introduction
The neuropeptides orexin A and orexin B, also called
hypocretin 1 and hypocretin 2, are produced in neurons located
in the lateral hypothalamic area (LHA). Disruption of orexin
signaling has been shown to result in narcolepsy in mice, dogs, and
humans, highlighting the critical roles of orexins in the
maintenance of wakefulness and in the regulation of rapid eye
movement (REM) sleep.
Intracerebroventricular administration of orexin into animals
has been shown to increase the amount of wakefulness,
accompanied by decreases in the amount of both NREM and
REM sleep [1]. These effects are likely mediated by activation of
monoaminergic neurons in the brain stem, which express high
numbers of orexin receptors [2]. Although orexins play a key role
in the sleep/wakefulness control system, with the activity of orexin
neurons increasing during wakefulness and decreasing during sleep
[3,4,5], it is as yet unclear how awake, freely-moving animals will
react to changes in the activity of orexin neurons.
Since orexin neurons act as stabilizers of sleep/wakefulness
states, receiving input from various brain regions [2], changes in
their activity of these neurons in each vigilance state may occur
secondarily to changes in sleep/wakefulness states. Alternative-
ly, the activity of orexin neurons may actively affect the
vigilance states of animals. The latter proposal is supported by
findings showing that the discharge of orexin neurons increases
before the end of both NREM and REM sleep, thereby
preceding by several seconds a return to wakefulness [4]. Orexin
neurons may therefore act as integrators, receiving input from
other brain regions and, accordingly, actively regulating
vigilance states [2].
This hypothesis is supported by the finding that optogenetic
excitation of orexin neurons results in increases in the probability
of an awakening event during both NREM and REM sleep,
although this excitation did not change the total amount of
wakefulness [6,7]. However, the consequences of the acute
inhibition of orexin neurons in freely behaving mice remain
unknown.
In this study, we utilized a pharmacogenetic technique called
‘‘Designer Receptors Exclusively Activated by Designer Drugs
(DREADD)’’ [8]. This method utilizes extrinsic muscarinic
receptors, (hM3Dq for excitation and hM4Di for inhibition), that
have lost their affinity for endogenous acetylcholine but can still be
activated by a synthetic and pharmacologically inert ligand,
clozapine-N-oxide (CNO). Activation of Gq-coupled hM3Dq by
CNO was previously shown to activate neurons through
phospholipase C-dependent (PLC) mechanisms [9]_ENREF_9.
We confirmed the effect of hM3Dq in orexin neurons by calcium
imaging (Fig. S1A)_ENREF_9. CNO can also stimulate Gi/o-
coupled hM4Di receptors, thereby activating inwardly rectifying
potassium 3 (Kir3) channels, resulting in membrane hyperpolar-
ization and neuronal silencing [8,10]. We also confirmed the
inhibitory effect of hM4Di in orexin neurons by calcium imaging
[11] (Fig. S1B).
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e20360Using transgenic mice in which Cre-recombinase is expressed
exclusively in orexin neurons (orexin-cre transgenic mice) [12], these
receptors were expressed solely on orexin neurons by transfection
with adeno-associated virus (AAV) vectors utilizing the flip-
excision method, which restores the open reading frame in a
Cre-dependent manner [13,14] (Fig. 1A). As stimulation of
GPCRs with a specific ligand has a longer effect on cellular
signaling than optical stimulation of chanelrhodopsin 2 (ChR2) ion
channels, the DREADD system can facilitate the examination of
the chronic effects of modulating the activity of orexin neurons. In
addition, since CNO is a stable substance that can cross the blood
brain barrier, it can be administered intraperitoneally with
minimum interference with the behavioral state in freely-moving
animals. Our results demonstrated that activation of orexinergic
tone results in increased wakefulness time, while inhibition of these
neurons results in reduced wakefulness.
Results
Expression of hM3Dq and hM4Di in Orexin Neurons
To obtain selective pharmacogenetic control of orexin neurons
in vivo, we injected a recombinant adeno-associated virus (AAV2)
containing a doubly-floxed inverted open reading frame encoding
hM3Dq (rAAV-DIO-HAhM3Dq) or hM4Di (rAAV-DIO-
HAhM4Di) (Fig. 1A) into the LHA of orexin-cre transgenic mice,
in which Cre-recombinase is highly and specifically expressed in
orexin-producing neurons. These AAV vectors facilitate the
expression of N-terminally HA-tagged hM3Dq or hM4Di
exclusively in Cre-expressing cells (see Methods).
Immunohistochemical staining of brain slice preparations
showed that HA- immunoreactivity was observed exclusively in
the LHA region of orexin-cre transgenic mice injected with rAAV-
DIO-HAhM3Dq or rAAV-DIO-HAhM4Di (Fig. 1B). HA-
immunoreactivity was robustly observed in dendrites and axons
as well as cell bodies of the LHA neurons. No detectable staining
was observed in wild type mice infected with the same viruses (not
shown). These observations suggest that hM3Dq and hM4Di were
specifically expressed in the LHA in a Cre-dependent manner.
Moreover, double staining with anti-orexin and anti-HA
antibodies revealed HA-immunoreactivity in most orexin-produc-
ing neurons throughout the hypothalamus in orexin-cre mice
bilaterally injected with rAAV-DIO-HAhM3Dq or rAAV-DIO-
HAhM4Di (Fig. 1C), confirming that hM3Dq and hM4Di were
expressed exclusively in orexin-producing neurons. We examined
the expression rates of hM3Dq and hM4Di throughout the
hypothalamus and found that 78.268.1% and 73.2610.9% of
orexin-immunoreactive neurons were positive for HA staining,
when rAAV-DIO-HAhM3Dq or rAAV-DIO-HAhM4Di was
injected into orexin-cre mice, respectively (n=3 each). We did not
detect any ectopic expression of hM3Da and hM4Di in non-
orexin-producing neurons.
Modulation of Orexinergic Activity by Intraperitoneal
CNO Administration
We implanted thin silicone tubes into the peritoneal space of
mice so that we could administer CNO with minimal perturba-
tion. The effects of excitatory hM3Dq were examined during the
light period, at the time of day when orexinergic activity is
minimal (Fig. S2, Experiment 1). Following intraperitoneal
injection of CNO at 13:00 [zeitgeber time (ZT) 4], into orexin-cre
mice expressing hM3Dq, the animals were sacrificed and fixed at
15:00 (ZT6). Similarly, the effect of CNO in mice expressing
hM4Di was examined during the dark period, when orexinergic
activity is maximal (Fig. S2, Experiment 2). CNO was injected
intraperitoneally, just before the light was turned off at 21:00
(ZT12), into orexin-cre mice expressing hM4Di, and the mice were
sacrificed and fixed at 23:00 (ZT14) for immunostaining. We used
wild type mice injected with rAAV-DIO-HAhM4Di as controls.
Hypothalamic slices of these mice were examined by double
staining with anti-orexin and anti-Fos antibodies to assess the
activity of these orexin neurons.
In wild type mice, in which orexin neurons did not express
hM3Dq or hM4Di, the number of double-labeled neurons (orexin-
positive neurons with Fos-positive nuclei) showed marked diurnal
fluctuation, with a lower level of double-labeling at ZT6
(8.461.1%) and higher level at ZT14 (44.764.3%) (Fig. 2A, C).
These findings are consistent with the results observed in
unmanipulated wild type mice (not shown) and previously
reported in rats [15].
When we examined rAAV-DIO-HAhM3Dq-injected orexin-cre
mice, we observed a 261.1% increase in double-labeled neurons
when compared with wild type controls in the light periods
(30.462.86% vs 8.461.1%) (Fig. 2A, B, E). Similarly, when we
assayed rAAV-DIO-HAhM4Di-injected orexin-cre mice, we ob-
served a 34.0% decrease in double-labeled neurons compared with
wild type mice in the dark periods (29.563.1% vs 44.764.3%)
(Fig. 2C, D, F). These observations demonstrate that the
DREADD system used in this study appropriately modulates the
activity of orexin neurons.
Modulation of Orexinergic Activity Alters Behavioral
States in Mice
To examine the effect of hM3Dq stimulation of orexin neurons
on sleep/wakefulness states, we first administered CNO or saline
intraperitoneally to orexin-cre mice, in which orexin neurons
specifically express hM3Dq, at ZT4 (Fig. S2, Experiment 1). The
sleep/wakefulness states of these mice were monitored by
simultaneous EEG/EMG recordings. As a control, we treated
the same mice with saline on separate experimental days.
We found that the percent of wakefulness during the one hour
after CNO administration was significantly greater (69.5612.4%
vs 43.867.9%, t5=-3.826, p=0.012) and NREM time was
significantly shorter (30.2610.3% vs 51.967.0%, t5=3.182,
p=0.024) in CNO-treated conditions than in saline-injected
control conditions (Fig. 3A, left panels, Fig. S3). These results
suggest that stimulation of orexin neurons results in increased
wakefulness time, accompanied by decreased NREM sleep time.
We also observed a significant decrease in REM sleep time
(0.3160.31% vs 4.3361.0%, t5=4.202, p=0.008).
We also examined the effect of stimulation during the dark
period to determine whether the pharmacogenetic activation of
orexin neurons can enhance the effect of endogenous orexinergic
activity (Experiment 2, Fig. S2). We administered CNO or saline
intraperitoneally to orexin-cre mice, in which orexin neurons
specifically express hM3Dq, at ZT12 (Fig. S2, Experiment 2).
We observed a modest effect on sleep/wakefulness states (Fig. 3,
right panels). In a one-two hour time window following the
injection, the wakefulness time was significantly longer in CNO-
treated orexin-cre mice (99.960.13% vs 96.361.1%, t5= =-3.098,
p=0.036). Also, we observed that latency from wakefulness to
REM sleep was longer in CNO-treated mice than in saline-treated
controls (448.2638.5 min vs 248.1675.1 min, t5=-3.003,
p=0.040; Fig 3B, right panel). These observations suggest that
pharmacogenetic activation of orexin neurons affects sleep/
wakefulness states in both the light and dark period.
Next, to test the effects of inhibition of orexin neurons on sleep/
wakefulness states, we administered CNO or saline intraperitone-
ally to orexin-cre mice, in which orexin neurons specifically express
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PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e20360Figure 1. Specific expression of hM3Dq and hM4Di in orexin neurons in mice. A, Schematic representation of double-floxed Cre-dependent
AAV vector expressing hM3Dq and hM4Di under control of EF-1a promoter (rAAV-DIO-HAhM3Dq and rAAV-DIO-HAhM4Di). DIO, double-floxed
inverted open reading frame; ITR, inverted terminal repeat; WPRE, woodchuck hepatitis virus post-transcriptional regulatory element. B, Coronal brain
sections at the level of LHA (bregma-1.8 mm), prepared from orexin-cre mice expressing hM3Dq or hM4Di following injection of Cre-dependent rAAV-
DIO-HAhM3Dq or rAAV-DIO-HAhM4Di. Sections were stained with anti-HA antibody. Scale bars, 40 mm. C, Upper panels, Coronal section of LHA
prepared from orexin-cre mice expressing hM3Dq and double stained with anti-orexin antibody (green) and anti-HA antibody (red), showing that
most of orexin-ir neurons express HAhM3Dq. Lower panels, Coronal section of LHA prepared from orexin-cre mice expressing hM4Di and double
stained with anti-orexin antibody (green) and anti-HA antibody (red), showing that most of orexin-ir neurons express HAhM4Di.
doi:10.1371/journal.pone.0020360.g001
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wakefulness during the one hour after CNO administration was
significantly shorter (69.065.0% vs 86.665.0%, t5= =6.492,
p=0.001), while NREM sleep time was significantly longer
(29.965.1% vs 12.764.8%, t5=-8.334, p=0.0004), in CNO-
treated mice than in controls (Fig. 4A, right pannels, Fig. S4).
These observations suggest that inhibition of orexin neurons
increases NREM time, accompanied by a decrease in wakefulness
time. We observed a slight increase in REM sleep time, although
this difference was not significant. The latency to NREM sleep was
significantly shorter in CNO-treated mice as compared with
controls (10.862.4 min vs 56.8618.6 min, t5=2.689, p=0.044;
Fig. 4B, right pannel).
We also examined whether inhibition in the light period can still
affect the sleep/wakefulness states of mice (Experiment 1, Fig. S2).
We administered CNO or saline intraperitoneally to orexin-cre
mice, in which orexin neurons specifically express hM4Di, at ZT4.
We observed a modest effect on sleep/wakefulness states (Fig. 4,
left panels). At one-two hours after injection, the wakefulness time
was significantly shorter (8.161.4% vs 17.062.3%, t5=3.437,
p=0.026) and NREM sleep was longer in CNO-treated mice
(84.663.0 min vs 73.461.5 min, t5=23.106, p=0.036). Inter-
estingly, REM sleep was significantly reduced in the first hour
following CNO administration (0.6760.3% vs 5.2261.5%,
t5=2.868, p=0.046), whereas latency to REM was significantly
increased in CNO-treated mice (55.561.9 min vs 34.664.8 min,
t5=24.813, p=0.009) (Fig. 4B, left panels).
Discussion
The expression of Fos, a marker of neuronal activity, in orexin
neurons in rats is increased during the dark, the period during
which rats are active and the awake state is dominant [15].
Moreover, orexin level in CSF peaks during dark period and
decreases during the light period, during which rats are inactive
and the sleep state is dominant [16]. In addition, in vivo
recording studies have shown changes in orexin neuronal
activity across the sleep-wake cycle [3,4,5]. Taken together,
these studies indicate that orexin neurons fire during active
waking, have decreased their discharge rates during quiet
waking, and virtually cease discharge during both REM and
NREM sleep.
The main effector sites for orexin are thought to be the
monoaminergic and cholinergic neurons in the brain stem. The
discharge rates of these neurons are strongly associated with sleep
and wakefulness, in that they fire tonically during awake periods,
less during NREM sleep, and are almost completely quiescent
during REM sleep [17], a pattern similar to the discharge of
orexin neurons. Orexin neurons and monoaminergic neurons in
the brain stem, including the locus coeruleus and dorsal raphe
nucleus, have a reciprocal interaction constituting a feedback
loop, thereby maintaining the activity of monoaminergic neurons
and perhaps explaining the similar discharge patterns of orexin
neurons and monoaminergic neurons [2]. Wake-active mono-
aminergic centers are also influenced by inhibitory projections
from the preoptic area, especially the ventrolateral preoptic area
(VLPO) [18]. Sleep may be maintained by VLPO sleep-active
neurons, which send inhibitory projections to both the hypotha-
lamic orexin neurons and brain stem monoaminergic neurons
[19,20]. These neural circuits may be important for the stability
of wakefulness [2]. We therefore performed this study to
determine the consequences of acutely changing orexinergic
tone, which is thought to be important in modulating these
circuits.
Figure 2. Activation or inhibition of orexin neurons by DREADD. A–D, Representative images of Fos expression in orexin neurons, as shown
by double staining of the LHA regions of wild type (A, C) and orexin-cre mice (B, D) injected with cre-activatable AAV carrying hM3Dq (A, B) or hM4Di
(C, D) (rAAV-DIO-HAhM3Dq or rAAV-DIO-HAhM4Di) after injection of CNO. A, Only a small numbers of Fos-IR nuclei were observed in orexin-
immunoreactive neurons from wild type mice administered CNO at 13:00 (ZT4) and killed at 15:00 (ZT6). Inset, high power view. B, Number of Fos-
and orexin-double-positive neurons was higher in orexin-cre than in wild type (A) administered CNO at ZT4 and killed at ZT6. Inset, high power view.
C, Many Fos- and orexin-double positive neurons were observed in wild type mice administered CNO at ZT12 and killed at ZT14. Inset, high power
view. D, Fewer Fos- and orexin-double-positive neurons were observed in orexin-cre than in wild type mice administered CNO at ZT12 and killed at
ZT14. Inset, high power view. E, Numbers of double-positive neurons at ZT6 in wild type and orexin-cre transgenic mice injected with hM3Dq virus
and administered CNO (N=5). F, Numbers of double-positive neurons at ZT14 in wild type and orexin-cre transgenic mice injected with hM4Di virus
and administered CNO (N=5).
doi:10.1371/journal.pone.0020360.g002
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in mice was performed demonstrated an increased probability of
transitions to wakefulness from NREM or REM sleep in mice [7].
The consequence(s) of the acute inhibition of orexin neurons in
freely behaving mice remain unknown. Although halorhodopsin-
mediated optogenetic inhibition techniques are available, we
found it difficult to acutely silence the orexinergic influence in the
brain, presumably because orexin A is a stable peptide in the
synaptic cleft and extracellular space. Therefore, the effects of
orexin are presumably not attenuated after transient halorhodop-
sin-mediated inhibition of orexin neurons.
In this study, we applied a new pharmacogenetic technique,
namely the DREADD technology [8,9,10,14], to phamacogeneti-
cally manipulate the activity of orexin neurons. We found that
pharmacogenetic stimulation of orexinergic tone resulted in an
increased wakefulness time during the light period (rest phase). We
also observed a modest effect even when we injected CNO in dark
periods (Fig 3A, right panels). Chronic photo-stimulation (15 ms
pulses at 20 Hz for 10 s every minute for 1 h) of orexin neurons
has been reported to increase the number of NREM sleep-to-wake
transitions but not to increase total wake time [6]. This suggests
that pharmacogenetic stimulation as used here has an advantage
in evoking more potent and chronic stimulation of orexin neurons
than does ChR2-mediated photo-stimulation, although the time
resolution of the former was not comparable to that of
photostimulation.
The inhibition of orexin neurons by hM4Di resulted in
increased NREM sleep time during the dark period (active
phase). DREADD utilizes G-protein coupled receptor signaling,
which can affect neuronal activity in a relatively chronic and
consistent manner, allowing investigation of the effects of orexin
neuron inhibition. We confirmed this action by intracellular
Figure 3. Effect of stimulation of orexinergic tone by hM3Dq on vigilance states of mice during light and dark periods (left and right
panels, respectively). A. Hourly analysis of sleep/wake states in transgenic and wild-type mice, both injected with rAAV-DIO-HAhM3Dq, after
administration of CNO at ZT4 or ZT12. Amounts of wakefulness (Wake, upper panels), NREM sleep (middle panels), and REM sleep (lower panels) are
shown. B, Latency to NREM sleep and REM sleep after CNO administration (N=6 for transgenic mice, N=5 for wild-type mice).
doi:10.1371/journal.pone.0020360.g003
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Compared with the effects of hM3Dq during the light periods,
the effects of hM4Di during the dark period were less striking.
Since the orexin peptide is a highly stable substance, decreasing
the activity of orexin neurons may not immediately induce a
decrease in the stimulatory effects of orexin on target cells. We
also observed modest effects of hM4Di activation even when we
administered CNO in the light period (Fig. 4A, left periods).
This suggests that although orexinergic activity is lowered in the
light period, further inhibition can affect sleep/wakefulness
states.
Interestingly, we observed that DREADD-mediated inhibition
resulted in shorter REM sleep time and longer REM latency one
hour after CNO administration. These results could suggest an
intriguing hypothesis that the activity of some population of orexin
neurons might be necessary to evoke a proper REM sleep period
in the rest period. This hypothesis should be further examined in
future studies.
Our findings have profound meaning for sleep physiology,
because many factors have been identified as influencing the
activity of orexin neurons. For example, decreasing extracellular
glucose concentration has been found to result in depolarization
and increased discharge of orexin neurons, while increasing
extracellular glucose concentration has been found to induce
hyperpolarization and the cessation of discharge [21,22]. Impor-
tantly, this mechanism is sufficiently sensitive to encode variations
in glucose levels in the cerebrospinal fluid reflecting those
occurring physiologically between normal meals [21,22]. There-
fore, changes in blood glucose concentration may influence an
animal’s vigilance states in daily life through orexin neurons.
Our findings have shown that specific changes in orexin
neuronal activity can affect an animal’s vigilance states. These
Figure 4. Effect of inhibition of orexinergic tone by hM4Di on vigilance states of mice during light and dark periods (left and right
panels, respectively). A. Hourly analysis of sleep/wake states in transgenic and wild-type mice, both injected with rAAV-DIO-HAhM4Di, after
administration of CNO at ZT4 or ZT12. Amounts of wakefulness (Wake, upper panels), NREM sleep (middle panels), and REM sleep (lower panels) are
shown. B. Latency to NREM sleep and REM sleep after CNO administration (N=5).
doi:10.1371/journal.pone.0020360.g004
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relevance of orexin neurons in the regulation of sleep/wakefulness
states.
Materials and Methods
Animals
All experimental procedures involving animals were approved
by the Animal Experiment and Use Committee of Kanazawa
University (AP-101567) and were in accordance with NIH 2009
guidelines. Generation of Orexin-cre mice was reported in our
previous study [12]. Mice were maintained under a strict 12 hour
light:dark cycle in a temperature- and humidity-controlled room
and fed ad libitum. All efforts were made to minimize animal
suffering and discomfort and to reduce the number of animals
used.
AAV production and purification
The plasmids pcDNA5/FRT-HA-hM3Dq and pcDNA5/FRT-HA-
hM4Di [8] were each digested with PmeI, and the fragments
containing HA-hM3Dq and HA-hM4D were ligated in the antisense
direction into blunted AscI and NheI sites of pAAV-double floxed-
hChR2(H134R)-EYFP-WPRE-pA [13], provided by Dr. Karl
Deisseroth of Stanford University, to yield the plasmids pAAV-
DIO-HAhM3Dq and pAAV-DIO-HAhM4Di, respectively.
Viruses were produced using a triple-transfection, helper-free
method, and purified using a modification of a published protocol
[23]. Briefly, 293A cells (Invitrogen), cultured in ten 100620 mm
cell culture dishes per viral vector, were transfected with pHelper
(Stratagene), pACG-2-Y730F [24] (containing a mutant form of
the cap gene of AAV2 and provided by Dr. Arun Srivastava of the
University of Florida), and pAAV-DIO-HAhM3Dq or pAAV-DIO-
HAhM4Di, using a standard calcium phosphate method. Three
days later, the cells were collected, pelleted and resuspended in
freezing buffer (10ml 0.15 M NaCl, 50 mM Tris, pH 8.0). After
two freeze-thaw cycles and subsequent centrifugation, each lysate
was treated with DNase I (40 mg/ml) and RNase A (40 mg/ml) and
then with deoxycholic acid (Sigma) (0.5%), followed by filtration,
as described previously [23]. Each cleared lysate was mixed with
1.5 ml of heparin-agarose suspension (Sigma) equilibrated with
freezing buffer, incubated with gentle rotation for 60 min at 4uC,
and loaded onto a Bio-Spin Column 100 (Bio-Rad Laboratories).
Each column was washed three times with 2 ml freezing buffer,
and viruses were eluted with 3 ml elution buffer (0.5 M NaCl,
50 mM Tris, pH 8.0). Each virus preparation was dialyzed against
1x PBS using Slide-A-Lyzer Dialysis Cassettes (Pierce) and
concentrated using Concentration Solution (Pierce). The final
purified viruses were stored at 280uC. The titers of rAAV-DIO-
HAhM3Dq and rAAV-DIO-HAhM4Di were 5.7610
12 and
2.6610
12 genome copies/ml, respectively.
Surgery
Male orexin-cre mice (10 to 12 weeks old) were anesthetized with
sodium pentobarbital (0.5 mg/kg, i.p.) and positioned in a
stereotaxic frame (David Kopf Instruments). Four holes were
drilled into the skull of each mouse, at sites 21.4 mm posterior,
60.9 mm lateral, and 25.5 mm ventral; and 21.8 mm posterior,
60.9 mm lateral, and 25.7 mm ventral relative to the bregma (4
injection sites per mouse). A Hamilton needle syringe (33 gauge)
was placed at each site, and 0.3 ml purified virus was delivered to
each site over a 10-min period. After 5 min of rest, the needles
were removed. The mice were sacrificed 14 days later, and tissue
samples were assayed by immunohistochemistry. Following virus
administration, an electrode for EEG and EMG recording was
implanted to the skull of each mouse. The three arms of the
electrode for EEG recording were placed approximately 2 mm
anterior and 2 mm to the right, 2 mm posterior and 2 mm to the
right, and 2 mm posterior and 2 mm to the left of the bregma.
Stainless steel wires for EMG recording were sutured to the neck
muscles of each mouse bilaterally, and each electrode was glued
solidly to the skull.
Silicon tubes were implanted for remote CNO injection. The tip
of a 30 cm-long silicon tube was inserted 1 cm into the peritoneal
cavity and sutured to the abdominal wall. The other end of the
silicon tube was placed outside the body through an incision in
neck, and all incisions were sutured.
All animals were then housed individually for a recovery period
of at least 7 days.
Drugs and administration
Clozapine N-oxide (CNO; C0832, Sigma-Aldrich) was dissolved
in saline to a concentration of 0.5 mg/ml. CNO was administered
by intraperitoneal injection to each mouse (0.3 ml/30 g body
weight) through the silicon tube, at ZT 4 in experiment 1 and at
ZT 12 in experiment 2.
Immunohistochemistry
Mouse brains were fixed and prepared as described previously
[25]. For double immunofluorescence analysis, cryostat sections
(40-mm thick) were preincubated for 1 h in 0.1 M phosphate
buffer containing 1% bovine serum albumin and 0.25% Triton-X-
100, and incubated overnight at 4uC with rabbit anti-orexin
(1:1000) and mouse anti-HA (Covance, 1:1000) antibodies in the
same solution. After three washes in the same solution, the sections
were incubated with Alexa 594-conjugated donkey anti-rabbit IgG
(Molecular Probes, 1:500) and Alexa 488-conjugated goat anti-
mouse IgG (Molecular Probes, 1:800) for 90 min at room
temperature. After three washes in 0.1 M phosphate buffer, the
sections were mounted on glass slides and cover-slipped. Slides
were examined by laser-confocal microscopy (Nikon, D-ECLIPSE
C1si). For other immunohistochemical assays, cryostat sections
(40-mm thick) were stained using the avidin-biotin-peroxidase
method. Sections were washed for 1 h in 0.1 M phosphate buffer
containing 1% bovine serum albumin and 0.25% Triton-X-100,
incubated overnight at 4uC with mouse anti-HA antibody, washed
three times, incubated for 1 h with biotinylated anti-mouse
antibody (Vector Labs, Burlingame, CA, 1:500), washed again
and processed using a Vectastain ABC kit (Vector Labs,
Burlingame, CA). After washing, the sections were mounted on
glass slides and cover-slipped. To detect Fos immunoreactivity in
orexin-expressing neurons, the sections were incubated with
guinea pig anti-orexin antibody (Molecular Probes, 1:1000; brown
color) and rabbit anti-cFos antibody Ab-5 (Calbiochem, 1:20000;
black color). The numbers of cFos-positive and negative orexin-
containing neurons were counted in coronal sections throughout
the hypothalamic region by a single examiner who was blinded to
treatment conditions, using an Olympus AX70 microscope. Cells
were counted on both sides of the brain in consecutive 40-mm
sections. Orexin neuron activity was scored as the percentage of
double-labeled cells per animal.
Sleep recordings
After the recovery period, animals were moved to a recording
cage placed in an electrically shielded and sound-attenuated room.
A cable for signal output was connected to the implanted electrode
and animals were allowed to move freely. Signals were amplified
through an amplifier (AB-611J, Nihon Koden, Tokyo) and
digitally recorded on a PC using EEG/EMG recording software
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seven days to adapt to the recording conditions prior to any EEG/
EMG recording session. Following the adaptation period, each
animal was injected with both CNO and saline on separate
experimental days with a 3-day interval. The order of injection (i.e.
either CNO first or saline first) was randomized. EEG/EMG data
were evaluated and staged for 24 hours on the day of CNO or
saline administration. Data acquired on the day of saline
administration were used as controls. After recording, the mice
were again administered CNO and their brain sections were
stained for Fos.
Statistical Analysis
For statistical analyses of sleep/wake data, Student’s paired t-
tests were run under the same software described above. Data
were expressed as mean6SEM. Differences were considered
significant at P,0.05.
Supporting Information
Figure S1 Typical example of responses of orexin neurons to
application of CNO as measured by intracellular calcium imaging.
Orexin-YC2.1;orexin-Cre double transgenic mice were injected with
rAAV-DIO-HAhM3Dq (A) or rAAV-DIO-HAhM4Di (B). Two
weeks later, brain slices from these mice were prepared and
subjected to calcium imaging as described previously [11]. CNO
application increased or decreased intracellular calcium levels of
orexin neurons, respectively. Cholecystokinin-8S (CCK-8S) (A) or
5-HT (B) was used as positive controls.
(TIF)
Figure S2 Experimental procedures.
(TIF)
Figure S3 A representative one-hour hypnograms showing the
effect of activation of orexin neurons showing effect of activation of
orexin neurons by DREADD. A, Representative one-hour
hypnograms for (A) wild type (WT) and (B) orexin-cre transgenic
(TG) mice injected with rAAV-DIO-HAhM3Dq after CNO
administration at ZT4.
(TIF)
Figure S4 A representative one-hour hypnograms showing the
effect of activation of orexin neurons showing effect of inhibition of
orexin neurons by DREADD. A, Representative one-hour
hypnograms for (A) wild type (WT) and (B) orexin-cre transgenic
(TG) mice injected with rAAV-DIO-HAhM4Di after CNO
administration at ZT12.
(TIF)
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